annb0t
Top 20
Things are looking better for the biotech industry in the second half of 2023 after a ho-hum performance in the first half and a bumpy ride in 2022 as the world cautiously wades through an uncertain macroeconomic environment. The outlook provided by most companies indicates better prospects due to new drug approvals and positive pipeline updates, which should help combat a recession. Meanwhile, most companies are looking to bolster their product portfolios through collaborations and buyouts. Hen...
>>> Read more: 5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
>>> Read more: 5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
